• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Celcuity Inc.

    11/13/25 5:33:48 PM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Celcuity Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    15102K100

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    15102K100


    1Names of Reporting Persons

    Brian F. Sullivan
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,647,994.00
    6Shared Voting Power

    365,209.00
    7Sole Dispositive Power

    3,647,994.00
    8Shared Dispositive Power

    365,209.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,013,203.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.1 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The shares reported include options to acquire 892,220 shares of common stock that have vested or will vest within 60 days of September 30, 2025. The ownership percentage reported is calculated based on 43,274,548 shares of common stock issued and outstanding as of September 30, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Celcuity Inc.
    (b)Address of issuer's principal executive offices:

    16305 36th Avenue North, Suite 100 Minneapolis MN 55446
    Item 2. 
    (a)Name of person filing:

    Brian F. Sullivan
    (b)Address or principal business office or, if none, residence:

    16305 36th Avenue North Suite 100 Minneapolis, MN 55446
    (c)Citizenship:

    UNITED STATES
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    15102K100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,013,203 shares, which includes (a) 1,897,210 shares of common stock held directly by Mr. Sullivan, including 892,220 shares of common stock of which Mr. Sullivan has the right to acquire beneficial ownership within 60 days of September 30, 2025; (b) 1,750,784 shares of common stock held through trusts of which Mr. Sullivan has sole voting and dispositive power; and (c) 365,209 shares of common stock held in a joint brokerage account with Mr. Sullivan's spouse of which he has shared voting and dispositive power.
    (b)Percent of class:

    9.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,647,994

     (ii) Shared power to vote or to direct the vote:

    365,209

     (iii) Sole power to dispose or to direct the disposition of:

    3,647,994

     (iv) Shared power to dispose or to direct the disposition of:

    365,209

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Brian F. Sullivan
     
    Signature:/s/ Brian F. Sullivan
    Name/Title:Brian F. Sullivan
    Date:11/13/2025
    Get the next $CELC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    11/18/2025$110.00Outperform
    Wolfe Research
    11/17/2025Buy → Neutral
    H.C. Wainwright
    9/22/2025$110.00Buy
    Guggenheim
    7/1/2025$30.00Buy
    Stifel
    7/22/2024$29.00Outperform
    Leerink Partners
    2/22/2024$40.00Buy
    Stifel
    12/8/2023$27.00Buy
    H.C. Wainwright
    10/8/2021$50.00Buy
    Canaccord Genuity
    More analyst ratings

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Celcuity with a new price target

    Wolfe Research initiated coverage of Celcuity with a rating of Outperform and set a new price target of $110.00

    11/18/25 8:21:08 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Celcuity from Buy to Neutral

    11/17/25 9:39:18 AM ET
    $CELC
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Celcuity with a new price target

    Guggenheim initiated coverage of Celcuity with a rating of Buy and set a new price target of $110.00

    9/22/25 8:29:54 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    SEC Filings

    View All

    SEC Form 144 filed by Celcuity Inc.

    144 - Celcuity Inc. (0001603454) (Subject)

    11/21/25 1:41:46 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Celcuity Inc. (0001603454) (Filer)

    11/17/25 4:36:18 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Celcuity Inc.

    SCHEDULE 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/25 4:06:01 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dalvey David sold $1,500,016 worth of shares (15,000 units at $100.00) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    11/24/25 4:07:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Buller Richard E gifted 500 shares, exercised 3,900 shares at a strike of $14.83 and sold $377,255 worth of shares (3,900 units at $96.73) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    11/21/25 4:14:32 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Nigon Richard exercised 7,917 in-the-money shares at a strike of $7.56, increasing direct ownership by 8% to 109,010 units (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/15/25 4:12:26 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

    MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data. Abstract presentation details are provided below. Abstract Title: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L

    11/26/25 4:05:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

    MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025. Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 7:30 a.m. ET on Wednesday, December 3, 2025. A live webcast of the event will be available using this weblink https://wsw.com/webcast/evercore52/celc/2320846. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.c

    11/26/25 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for gedatolisib in hormone receptor positive ("HR+"), human epidermal growth factor receptor 2 negative ("HER2-"), advanced breast cancer ("ABC"). The NDA was submitted under the FDA's Real-Time Oncology Review ("RTOR") program, which is intended to facilitate shorter regulatory review periods. Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on p

    11/17/25 4:05:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $9,571,319 worth of shares (170,100 units at $56.27) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/10/25 4:06:15 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Leadership Updates

    Live Leadership Updates

    View All

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Celcuity Appoints Eldon Mayer as Chief Commercial Officer

    MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

    2/20/24 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

    Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors."We are delighted to welcome Dr. Murphy to our Board and look forward to leveraging her business development expertise and broad industry experience as we continue to advance our pipeline," said Brian Sullivan, CEO and Co-Founder of Celcuity.Dr. Murphy joins Cel

    9/14/22 9:00:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:12 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:16 PM ET
    $CELC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Celcuity Inc.

    SC 13G - Celcuity Inc. (0001603454) (Subject)

    11/14/24 4:26:12 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Financials

    Live finance-specific insights

    View All

    Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webli

    11/5/25 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

    Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and in 11.5% of patients treated with gedatolisib + fulvestrant ("gedatolisib doublet")Study treatment discontinuation due to treatment related adverse events was reported in 2.3% of patients treated with the gedatolisib triplet and 3.1% of patients with the gedatolisib doubletManagement to host webcast and conference call October 20, 2025, at 8:00 a.m. ET MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing

    10/18/25 4:30:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink:

    8/7/25 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care